Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces antitumoral immune responses

Oncotarget. 2017 Jul 18;8(29):47440-47453. doi: 10.18632/oncotarget.17663.

Abstract

Tumor immunotherapy aims to overcome the immunosuppressive microenvironment within tumors, and various approaches have been developed. Tumor-associated T regulatory cells (Tregs) suppress the activation and expansion of tumor antigen-specific effector T cells, thus, providing a permissive environment for tumor growth. Therefore, optimal strategies need to be established to deplete tumor-infiltrated Tregs because systemic depletion of Tregs can result in reduced anti-tumor effector cells and autoimmunity. Here, to selectively deplete Tregs in tumors, we intratumorally injected anti-CD25 antibodies conjugated to Chlorin e6 (Ce6), a photosensitizer that absorbs light to generate reactive oxygen species. Local depletion of tumor-associated Tregs with photodynamic therapy (PDT) inhibited tumor growth, which was likely due to the altered tumor immune microenvironment that was characterized by increased infiltration of CD8+ effector T cells and the expression of IFN-γ and CD107a, which is a cytolytic granule exocytosis marker in tumor tissues. Furthermore, PDT-induced intratumoral Treg depletion did not influence adaptive immune responses in a murine influenza infection model. Thus, our results show that intratumoral Treg-targeted PDT could specifically modulate tumor microenvironments by depleting Tregs and could be used as a novel cancer immunotherapy technique.

Keywords: CD25; Chlorin e6; Treg; immunotherapy; photodynamic therapy.

MeSH terms

  • Adaptive Immunity
  • Animals
  • Apoptosis
  • Biomarkers
  • Cytotoxicity, Immunologic
  • Disease Models, Animal
  • Humans
  • Immunophenotyping
  • Immunotherapy
  • Interleukin-2 Receptor alpha Subunit / metabolism*
  • Lymphocyte Depletion* / methods
  • Lymphocytes, Tumor-Infiltrating / immunology*
  • Lymphocytes, Tumor-Infiltrating / metabolism*
  • Male
  • Melanoma / immunology*
  • Melanoma / metabolism*
  • Melanoma / pathology
  • Melanoma / therapy
  • Melanoma, Experimental
  • Mice
  • Photochemotherapy
  • T-Lymphocytes, Regulatory / immunology*
  • T-Lymphocytes, Regulatory / metabolism*
  • Xenograft Model Antitumor Assays

Substances

  • Biomarkers
  • Interleukin-2 Receptor alpha Subunit